ALKERMES | ALKS - 股票

金融业

USD

USD 4.26B

现金及等价物

USD 351.55M

USD 73.25M

USD 1.36B

USD 599.5M

USD 1.58B

股息收益率

0

USD -48.28M

USD 80.26M

1.8K

EPS每股收益

USD -0.4

股本和储备

USD 1.75B

USD 331.33M

债务利息支出

USD 20.89M

USD 8.54M

USD 1.48B

USD 5.98B

USD -66.48M

USD 1.75B

USD -48.28M

普通股股本

USD 166.46M

39.33

USD -61.93M

USD 392.91M

销售和管理费用

USD 264.59M

USD 336.7M

贸易债权人

USD 102.36M

应收帐款人

USD 407.63M

	股票	更改		日
AbbVie	USD 5.05B		98M	2026-03
Acadia Pharmaceuticals	USD 31.57M		3.1M	2026-03
ALKERMES	USD 336.7M		140.08M	2026-03
Amgen	USD 6.19B		39M	2026-03
Biogen	USD 1.95B		219.1M	2026-03
BioMarin Pharmaceutical	USD 1.27B		25.66M	2026-03
Bristol-Myers Squibb	USD 2.76B		66M	2026-03
Coherus Biosciences	USD 3.17M		1.12M	2025-12
Eli Lilly	USD 14.53B		785M	2026-03
Gilead Sciences	USD 1.91B		140M	2026-03
Heron Therapeutics	USD 54.57M		2.33M	2022-12
Ionis Pharmaceuticals	USD 5.56M		4.49M	2026-03
J&J	USD 14.58B		392M	2026-03
Merck	USD 6.48B		179M	2026-03
Nektar Therapeutics	USD 14.46M		1.78M	2024-06
Neurocrine Biosciences	USD 64.5M		4.5M	2026-03
Otsuka Holdings	JPY 374.32B		23.79B	2025-12
Pfizer	USD 10.67B		13M	2026-03
Regeneron Pharmaceuticals	USD 3.1B		97.2M	2026-03
Vertex Pharmaceuticals	USD 1.77B		79.9M	2026-03